Aquestive's Allergy Drug Stalls at the FDA While Lawsuits Pile Up — Can Investors Afford to Wait for a Turnaround?

Shares of Aquestive Therapeutics sank another 11.6% to $4.41 on June 25, extending a brutal stretch for a company whose entire investment case hinges on a single product: a dissolve-under-the-tongue epinephrine film designed to replace the EpiPen needle for severe allergy emergencies. No fresh catalyst triggered today's drop — it is the grinding continuation of two overlapping crises that have slashed investor confidence since January.

The FDA Rejected the Drug Application, and the Fix Isn't Simple. On January 30, the FDA issued a Complete Response Letter — essentially a formal rejection — citing deficiencies related to "human factors validation," including problems with pouch opening and film placement, plus a request for an additional study.

The company says it expects to resubmit as early as Q3 2026 , but every month of delay is a month without revenue from its flagship product. Q1 2026 revenue was just $14.45 million, with a net loss of $5.63 million.

A Fraud Lawsuit Alleges the CEO Knew About the Problems. The securities class action claims management "created a false impression" that the drug application was on track for approval, causing investors to buy shares at prices that didn't reflect the true regulatory risks.

CEO Daniel Barber is named as an individual defendant.

Shares crashed from $6.21 to $3.91 — a $2.30-per-share loss — the day the FDA issues surfaced in January. The litigation adds legal costs and a cloud of uncertainty that makes institutional buyers reluctant to step in.

Wall Street Cut Its Targets, but Still Says "Buy" — A Puzzling Split. Cantor slashed its price target from $15 to $8 in January.

Alliance Global later cut to $9 from $12, keeping a Buy rating.

The current median analyst target sits around $9.00 — roughly double today's price — but that optimism depends entirely on a successful resubmission and eventual approval, outcomes that remain uncertain.

Cash Buys Time, but Not Forever. Aquestive reported roughly $120 million in cash as of year-end 2025 , and 2026 revenue guidance projects up to $50 million. That runway is real, but the company remains loss-making. Delays or setbacks for the allergy film "could weigh heavily on a company that is still loss-making and reliant on this asset for future revenue." Until the FDA clears a path forward, today's price reflects a market that is pricing in risk, not promise.